Destiny Pharma Seeks AIM Listing To Advance First-In-Class Antibiotics

 
• By Sten Stovall

UK-based Destiny Pharma hopes its planned IPO will attract investor demand, backed by its promise of new anti-microbial drugs and the huge innovation gap in antibacterial development.

Doctor holding in hand Antibiotic Resistance
Destiny Pharma IPO To Fund Its XF Antibiotic Platform • Source: Shutterstock

More from Strategy

More from Business